Nuvectis Pharma (Nuvectis Pharma) Net Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Nuvectis Pharma's Net Income for the three months ended in Mar. 2024 was $-4.17 Mil. Nuvectis Pharma's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Nuvectis Pharma's net margin for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Nuvectis Pharma's Net Margin % or its related term are showing as below:

NVCT's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.36
* Ranked among companies with meaningful Net Margin % only.

Nuvectis Pharma Net Margin % Historical Data

The historical data trend for Nuvectis Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma Net Margin % Chart

Nuvectis Pharma Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Margin %

Nuvectis Pharma Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Margin %	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Nuvectis Pharma's Net Margin %

For the Biotechnology subindustry, Nuvectis Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvectis Pharma's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Nuvectis Pharma's Net Margin % falls into.

Nuvectis Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Nuvectis Pharma's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-22.26	/	0
	=	%

Nuvectis Pharma's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin	=	Net Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-4.171	/	0
	=	%

Nuvectis Pharma (NAS:NVCT) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Nuvectis Pharma Net Margin % Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvectis Pharma (Nuvectis Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024

Website

https://www.nuvectis.com

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. Its pipeline products include NXP800, NXP900.

Executives

Ron Bentsur	director, officer: Chairman & CEO	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Marlio Charles Mosseri	10 percent owner	27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Enrique Poradosu	officer: Chief Science and Business Off	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Shay Shemesh	officer: Chief Development Officer	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Michael J. Carson	officer: Vice President, Finance	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Kenneth Hoberman	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii	director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or	officer: Int. Principal Financial Off.	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan	director	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024